Terms: = Lymphoma AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
581 results:
1. Renin-Angiotensin System Inhibitors Suppress the Growth of Leukemia Cells.
Itoh M; Sasaki S; Tohda S
Anticancer Res; 2024 Mar; 44(3):1183-1192. PubMed ID: 38423665
[TBL] [Abstract] [Full Text] [Related]
2. Sestrin 2 protects human lens epithelial cells from oxidative stress and apoptosis induced by hydrogen peroxide by regulating the mtor/Nrf2 pathway.
Tian X; Wei J
Int J Immunopathol Pharmacol; 2024; 38():3946320241234741. PubMed ID: 38379215
[TBL] [Abstract] [Full Text] [Related]
3. Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-
Liang X; Yu H; Liang R; Feng Z; Saidahmatov A; Sun C; Ren H; Wei X; Zhao J; Yang C; Liu H
J Med Chem; 2024 Feb; 67(4):2884-2906. PubMed ID: 38349664
[TBL] [Abstract] [Full Text] [Related]
4. In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mtor pathway.
Diab SE; Tayea NA; Elwakil BH; Elshewemi SS; Gad AAEM; Abdulmalek SA; Ghareeb DA; Olama ZA
Sci Rep; 2024 Jan; 14(1):2433. PubMed ID: 38286826
[TBL] [Abstract] [Full Text] [Related]
5. Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides.
Bordeaux ZA; Reddy SV; Choi J; Braun G; McKeel J; Lu W; Yossef SM; Ma EZ; West CE; Kwatra SG; Kwatra MM
Sci Rep; 2024 Jan; 14(1):1955. PubMed ID: 38263212
[TBL] [Abstract] [Full Text] [Related]
6. Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p/Casitas B-lineage lymphoma axis-mediated activation of the phosphoinositide 3-kinase/Akt pathway.
Feng X; Yang L; Liu X; Liu M; Liu L; Liu J; Luo J
Med Oncol; 2024 Jan; 41(2):60. PubMed ID: 38252204
[TBL] [Abstract] [Full Text] [Related]
7. ATF5 promotes malignant T cell survival through the PI3K/AKT/mtor pathway in cutaneous T cell lymphoma.
Cao M; Lai P; Liu X; Liu F; Qin Y; Tu P; Wang Y
Front Immunol; 2023; 14():1282996. PubMed ID: 38223508
[TBL] [Abstract] [Full Text] [Related]
8. Targeting HDACs for diffuse large B-cell lymphoma therapy.
Wu C; Song Q; Gao S; Wu S
Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
[TBL] [Abstract] [Full Text] [Related]
9. The gene expression profile and cell of origin of canine peripheral T-cell lymphoma.
Owens E; Harris L; Harris A; Yoshimoto J; Burnett R; Avery A
BMC Cancer; 2024 Jan; 24(1):18. PubMed ID: 38166662
[TBL] [Abstract] [Full Text] [Related]
10. The role of α7-nAChR-mediated PI3K/AKT pathway in lung cancer induced by nicotine.
He Z; Xu Y; Rao Z; Zhang Z; Zhou J; Zhou T; Wang H
Sci Total Environ; 2024 Feb; 912():169604. PubMed ID: 38157907
[TBL] [Abstract] [Full Text] [Related]
11. [Saikosaponin D regulates apoptosis and autophagy of pancreatic cancer Panc-1 cells via Akt/mtor pathway].
Guan YH; Liu GM; Liu YS; Lan LB; Zheng R; Liu XB
Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(19):5278-5284. PubMed ID: 38114117
[TBL] [Abstract] [Full Text] [Related]
12. Homoharringtonine induces apoptosis of mammary carcinoma cells by inhibiting the AKT/mtor signaling pathway.
Zhang X; Mei C; Liang Z; Zhi Y; Xu H; Wang H; Dong H
Vet Comp Oncol; 2024 Mar; 22(1):57-69. PubMed ID: 38081660
[TBL] [Abstract] [Full Text] [Related]
13. A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
Al-Kali A; Aldoss I; Atherton PJ; Strand CA; Shah B; Webster J; Bhatnagar B; Flatten KS; Peterson KL; Schneider PA; Buhrow SA; Kong J; Reid JM; Adjei AA; Kaufmann SH
Cancer Med; 2023 Dec; 12(23):21229-21239. PubMed ID: 37960985
[TBL] [Abstract] [Full Text] [Related]
14. Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations.
Seront E; Van Damme A; Legrand C; Bisdorff-Bresson A; Orcel P; Funck-Brentano T; Sevestre MA; Dompmartin A; Quere I; Brouillard P; Revencu N; De Bortoli M; Hammer F; Clapuyt P; Dumitriu D; Vikkula M; Boon LM
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937645
[TBL] [Abstract] [Full Text] [Related]
15. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.
Kondo N; Utsumi T; Shimizu Y; Takemoto A; Oh-Hara T; Uchibori K; Subat-Motoshi S; Ninomiya H; Takeuchi K; Nishio M; Miyazaki Y; Katayama R
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37917191
[TBL] [Abstract] [Full Text] [Related]
16. [New treatment strategies for primary lymphoma of the central nervous system].
Seidel S; Kaulen L; von Baumgarten L
Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
[TBL] [Abstract] [Full Text] [Related]
17. Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.
Xia Y; Zhang L; He W; Pan H; Fang J; Cui G
Cancer Biol Ther; 2023 Dec; 24(1):2271212. PubMed ID: 37906510
[TBL] [Abstract] [Full Text] [Related]
18. Inhibition of the NOTCH and mtor pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
Chang YS; Gills JJ; Kawabata S; Onozawa M; Della Gatta G; Ferrando AA; Aplan PD; Dennis PA
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37800623
[TBL] [Abstract] [Full Text] [Related]
19. Bcl-3 regulates T cell function through energy metabolism.
Liu H; Zeng L; Pan M; Huang L; Li H; Liu M; Niu X; Zhang C; Wang H
BMC Immunol; 2023 Oct; 24(1):35. PubMed ID: 37794349
[TBL] [Abstract] [Full Text] [Related]
20. Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME; Koirala S; Sloan S; Brown-Burke F; Weigel C; Villagomez L; Corps K; Sharma A; Hout I; Harper M; Helmig-Mason J; Tallada S; Chen Z; Scherle P; Vaddi K; Chen-Kiang S; Di Liberto M; Meydan C; Foox J; Butler D; Mason C; Alinari L; Blaser BW; Baiocchi R
Blood Adv; 2024 Jan; 8(1):150-163. PubMed ID: 37782774
[TBL] [Abstract] [Full Text] [Related]
[Next]
